LABP Landos Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LABP

Price (delayed)

$22.235

Market cap

$69.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.5

Enterprise value

$31.75M

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of ...

Highlights
The company's EPS has surged by 64% YoY and by 7% QoQ
The company's net income rose by 44% YoY but it fell by 4.2% QoQ
LABP's quick ratio is down by 21% since the previous quarter and by 17% year-on-year
Landos Biopharma's equity has decreased by 19% YoY and by 16% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.landosbiopharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of LABP
Market
Shares outstanding
3.12M
Market cap
$69.3M
Enterprise value
$31.75M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.18
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$21.94M
EBITDA
-$21.94M
Free cash flow
-$20.48M
Per share
EPS
-$3.5
Free cash flow per share
-$3.26
Book value per share
$10.2
Revenue per share
$0
TBVPS
$6.06
Balance sheet
Total assets
$38.04M
Total liabilities
$6.25M
Debt
$0
Equity
$31.79M
Working capital
$31.79M
Liquidity
Debt to equity
0
Current ratio
6.09
Quick ratio
6.01
Net debt/EBITDA
1.71
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49.1%
Return on equity
-54.9%
Return on invested capital
N/A
Return on capital employed
-69%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LABP stock price

How has the Landos Biopharma stock price performed over time
Intraday
-0.07%
1 week
0.11%
1 month
3.47%
1 year
-23.33%
YTD
507.51%
QTD
3.51%

Financial performance

How have Landos Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$22.73M
Net income
-$21.94M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 44% YoY
The company's net income rose by 44% YoY but it fell by 4.2% QoQ

Growth

What is Landos Biopharma's growth rate over time

Valuation

What is Landos Biopharma stock price valuation
P/E
N/A
P/B
2.18
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 64% YoY and by 7% QoQ
Landos Biopharma's equity has decreased by 19% YoY and by 16% from the previous quarter

Efficiency

How efficient is Landos Biopharma business performance
The company's return on equity rose by 31% YoY but it fell by 9% QoQ
LABP's ROA is up by 28% YoY but it is down by 8% QoQ

Dividends

What is LABP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LABP.

Financial health

How did Landos Biopharma financials performed over time
LABP's current ratio is down by 22% from the previous quarter and by 18% YoY
LABP's quick ratio is down by 21% since the previous quarter and by 17% year-on-year
The debt is 100% smaller than the equity
Landos Biopharma's equity has decreased by 19% YoY and by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.